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Edited by Ivan SadowskiAbstract Although PDZK1 is a well-known adaptor protein,
the mechanisms for its role in transcriptional regulation are lar-
gely unknown. The peroxisome proliferator-activated receptor
alpha (PPARa) is a ligand-activated transcription factor that
plays an important role in the regulation of lipid homeostasis.
Previously, we established a tetracycline-regulated human cell
line that can be induced to express PPARa and identiﬁed candi-
date target genes, one of which was PDZK1. In this study, we
cloned and characterized the promoter region of the human
pdzk1 gene and determined the PPAR response element. Finally,
we demonstrate that endogenous PPARa regulates PDZK1
expression.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PDZK1 [1], also called C-terminal linking and modulating
protein (CLAMP) [2], contains four PDZ-binding domains,
which are involved in interactions between many diﬀerent pro-
teins in a variety of cellular contexts [3]. In the liver, PDZK1
interacts with the scavenger receptor class B type I (SR-BI)
and up-regulates SR-BI expression at the protein level [2,4].
SR-BI plays a critical role in lipoprotein metabolism, mainly
due to its ability to mediate selective high density lipoprotein
(HDL) cholesterol uptake [5]. In PDZK1 knockout mice, he-
patic SR-BI protein expression levels were dramatically re-Abbreviations: PPAR, peroxisome proliferator-activated receptor;
RXR, retinoid X receptor; PPRE, peroxisome proliferator responsive
element
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PDZK1 is important for modulating the lipoprotein metabo-
lism via up-regulation of SR-BI expression [3]. However, the
mechanism for transcriptional regulation of PDZK1 expres-
sion is largely unknown.
The peroxisome proliferator-activated receptor alpha
(PPARa) is a ligand-activated transcription factor that belongs
to the nuclear hormone receptor superfamily [7]. PPARa binds
to a direct repeat of two hexanucleotides spaced by one nucleo-
tide, as heterodimers with the retinoid X receptor (RXR) [8].
PPARa activators have been used to treat dyslipidemia, causing
a reduction in plasma triglyceride and elevation of HDL choles-
terol [9]. Previously, to identify humanPPARa responsive target
genes, we established a tightly tetracycline (Tet)-regulated hu-
man hepatoblastoma cell line that can be induced to express hu-
man PPARa (HepG2-tet-oﬀ-hPPARa) [10]. Our microarray
analyses using HepG2-tet-oﬀ-hPPARa cells indicated that
PPARa induced the expression of several genes involved in
the b-oxidation of fatty acids and others. Therefore, we think
it possible that we could identify the novel targets for PPARa
genes from these candidates. Indeed, we observed that PPARa
induces human PDZK1mRNA in these cells, although PDZK1
has not been reported as a direct PPAR target gene.
Here, we examined the relationship between PPARa and
PDZK1. To gain new insights into the transcriptional regula-
tion of PDZK1, we cloned and characterized the promoter re-
gion of PDZK1. We demonstrated that PPARa regulates the
expression of PDZK1 via the peroxisome proliferator respon-
sive element (PPRE).2. Materials and methods
2.1. Plasmid construction
A human PDZK1 promoter fragment spanning 4689 to +38 bp
was obtained by means of PCR with a human genomic BAC clone
(354F1, Invitrogen) and cloned into PGV-B vector (Toyo Ink) to gen-
erate a reporter plasmid (pPDZK1-4689). Deletion constructs wereblished by Elsevier B.V. All rights reserved.
Fig. 1. Nucleotide sequence of 1-kb 5 0-ﬂanking region of the human pdzk1 gene. The transcription initiation site determined by the CapSite Hunting
was assigned as +1. The positions of gene-speciﬁc antisense primers used for the CapSite Hunting method are marked by double underlines. The
translation initiation codon ATG is indicated by box. Underlined nucleotides are potential transcription factor binding sites proposed by TESS and
ERTargetDB.
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pPDZK1-4689(mut), was constructed by introducing point mutations
into the PDZK1 promoter using PCR methods. All constructs were
veriﬁed by sequencing.
2.2. Cell culture, transfection and reporter gene assays
HepG2 and Huh-7 cells were cultured in Dulbeccos Modiﬁed Ea-
gles Medium (DMEM) containing 7.5% fetal bovine serum (FBS).
For ligand treatments, cells were cultured in DMEM supplemented
with 10% charcoal/dextran treated FBS (HyClone) and either ligand
or DMSO. Luciferase assays were performed as described previously
[10]. Brieﬂy, HepG2 cells (4 · 104 cells/well) were seeded in 96-well
plates 14–18 h before transfection. The cells were transfected with
80 ng of the reporter plasmid, 20 ng of phRL-TK (Promega) and either
10 ng of pcDNA3 or pcDNA3-hPPARa expression vector. Twenty-
four hours after transfection, the cells were treated with DMSO or
100 lM fenoﬁbric acid. After 24 h, both ﬁreﬂy and Renilla luciferase
activities were quantiﬁed using a Dual-Luciferase Reporter Assay
System (Promega).
2.3. Analysis of the 5 0-ﬂanking sequence
The transcription initiation site of the human pdzk1 gene was deter-
mined by the CapSite Hunting method [11] with a human kidney Cap-
Site cDNA library (Nippon Gene) according to the manufacturers
instructions. Brieﬂy, the ﬁrst round of PCR was performed using a
sense DNA primer complementary to a 38-mer speciﬁc oligonucleotide
(rOligo) paired with the gene-speciﬁc antisense primer 1 (PDZK1-1)(Fig. 1). Nested PCR was performed using a nested sense DNA primer
complementary to rOligo paired with the nested gene-speciﬁc antisense
primer 2 (PDZK1-2) (Fig. 1). The PCR products were separated, iso-
lated and subcloned into a pGEM-T Easy vector (Promega). Eleven
independent clones were sequenced. Potential binding sites for tran-
scription factors were identiﬁed using Transcription Element Search
Software (TESS, http://www.cbil.upenn.edu/tess) which is based on
TRANSFAC v6.0 database and ERTargetDB, a database for mam-
malian estrogen receptor alpha (ERa) target promoters [12].
2.4. Electrophoretic mobility shift assay (EMSA)
Human PPARa and human RXRa proteins were prepared using the
IMPACT -CN system (New England Biolabs). EMSAs were per-
formed as described previously [10]. Supershift assays were performed
using anti-human PPARa (H0723, Perseus Proteomics), anti-human
RXRa (K8508, Perseus Proteomics) or anti-glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (MAB374, Chemicon International)
antibodies. Double-stranded oligonucleotides composed of the follow-
ing sequences were used for the binding and competition assays: hu-
man PDZK1 PPRE wild type, 5 0-GAAGCAGGACAGAGGT-
CACTTG-30; PDZK1 PPRE mutant, 5 0-GAAGCAGcAttGtcGT-
CACTTG-30, and rat acyl-CoA oxidase (ACO) PPRE, 5 0-GCGGAC-
CAGGACAAAGGTCACGTTC-3 0.
2.5. Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as described previously [10,13]. Anti-
bodies for PPARa (H-98, Santa Cruz), RXRa (D-20, Santa Cruz) or
Fig. 2. PPARa modulates human PDZK1 promoter activity via a PPRE. (A) Schematic representation of the human PDZK1 promoter. (B, C)
HepG2 cells were co-transfected with the indicated reporter plasmids, phRL-TK and either pcDNA3 or pcDNA3-hPPARa. Transfected cells were
treated with 100 lM fenoﬁbric acid (FEN) or DMSO (Vehicle) for 24 h and the cells were used for reporter gene assays. Luciferase activities from
reporter plasmids were normalized to Renilla luciferase activities. Values are expressed as fold induction of the control set as 1. Values represent the
mean ± S.E.M. (n = 3–7). Signiﬁcant diﬀerences of the values compared to the vehicle were determined using Dunnetts test (*P < 0.05, **P < 0.01,
***P < 0.001).
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precipitated DNAs were analyzed by PCR using the primers 5 0-TAT-
CTGCCAAAGGGAGAGTACCA-3 0 and 5 0-CAAGGAGGACAC-
GAGCAGTT-3 0, which ﬂanked the PPRE of the PDZK1.
2.6. Quantitative RT-PCR
RT-PCR was performed as previously described [10]. Brieﬂy, the
ﬁrst strand cDNA was synthesized from total RNA. The cDNAs were
used as templates for individual PCR reactions using speciﬁc primer
sets.
2.7. Western blotting
The cell lysates were resolved by 10% SDS–PAGE and electroblot-
ted to nitrocellulose membranes. Western blot analyses were carried
out using anti-human PDZK1 (PA3-16818, Aﬃnity BioReagents) or
anti-GAPDH antibodies. The intensity of each band was quantiﬁed
by ImageJ software (National Institutes of Health; freeware from
http://rsb.info.nih.gov/ij/).3. Results and discussion
3.1. Analysis of the 5 0-ﬂanking sequence of the human PDZK1
promoter
Previously, we found that PDZK1 was up-regulated by li-
gand-activated PPARa from the DNA microarray analyses
using HepG2-tet-oﬀ-hPPARa cells [10]. To investigate how
PPARa aﬀects PDZK1 mRNA expression, we analyzed the
5 0-ﬂanking region of the human pdzk1 gene. Because the pro-
moter region of the pdzk1 gene has not yet been cloned and
characterized, we ﬁrst identiﬁed the transcription initiation site
of the human pdzk1 gene by the CapSite Hunting method [11].
A single PCR product was identiﬁed (data not shown) and the
results of sequencing analysis of the PCR product demon-
strated that 11 independent clones show the same transcription
initiation site. The transcription initiation site was 19356 bp
upstream of the translation initiation codon (GenBank Acces-
sion No. AL390725) (Fig. 1). We designated this site as +1. We
next analyzed the ﬁrst 1-kb (1000/+1) of the 5 0-ﬂanking se-quence for transcription factor binding sites with the software
TESS and ERTargetDB (Fig. 1). The results indicated that an
atypical TATA sequence is located at nucleotide 54. We
found that the pdzk1 gene had a consensus sequence of ER re-
sponse element at position 977 to 963 bp (Fig. 1). Indeed,
PDZK1 expression is induced by b-estradiol in the breast can-
cer cell line which expresses ERa [14]. However, further inves-
tigations are necessary to deﬁne the molecular mechanisms of
the pdzk1 gene expression.
3.2. PPARa activates the PDZK1 promoter
To determine whether PPARa regulates PDZK1 promoter
activity, the human PDZK1 promoter corresponding to the re-
gion 4689 to +38 bp was fused to the luciferase gene in the
PGV-B basic vector to yield the reporter plasmid. We co-trans-
fected either the PPARa expression plasmid (PPARa, the
dashed and black bars shown in Fig. 2) or the vector plasmid
as a control (pcDNA3, the white and gray bars shown in
Fig. 2) together with the reporter plasmid (pPDZK1) into
HepG2 cells. These cells were subsequently incubated with
either fenoﬁbric acid (FEN, the gray and black bars shown
in Fig. 2) or DMSO (Vehicle, the white and dashed bars shown
in Fig. 2) for 24 h and used for reporter gene assays.
A 3.5-fold induction of the luciferase activity of the
pPDZK1-4689 reporter plasmid was observed upon transfec-
tion of PPARa (Fig. 2B, PPARa+Vehicle versus pcDNA3+
Vehicle using the pPDZK1-4689 construct). Addition of the
fenoﬁbric acid, a PPARa ligand, resulted in a further increase
in promoter activity. A 7.4-fold induction of luciferase activity
was observed (Fig. 2B, PPARa+FEN versus pcDNA3+Vehicle
using the pPDZK1-4689 construct). These results suggested
that human PDZK1 promoter is regulated by PPARa. To
localize the region within the PDZK1 promoter that confers
transcriptional responsiveness to ligand-activated PPARa, we
carried out 5 0 deletion analyses. Although the induction of
luciferase activity by PPARa was observed using four deletion
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pPDZK1-401), a further 5 0 deletion construct (pPDZK1-85)
was not induced by PPARa (Fig. 2B). These results indicated
that a functional PPRE may be located in the region between
401 and 85 bp of the human PDZK1 promoter. Indeed, we
found a putative PPRE sequence at position 98 to 86 bp
(Figs. 1 and 2A). In order to check whether this sequence is
a functional PPRE, we measured the luciferase activity of
the PPRE mutation construct (pPDZK1-4689(mut)). We
found that mutation of this PPRE abolished transcriptional
activation of the promoter by PPARa (Fig. 2C). These results
indicated that the 98 to 86 bp site in the human PDZK1
promoter is a positive PPRE.3.3. Binding analysis of PPARa to the human PDZK1 promoter
To determine whether PPARa binds to this PPRE in the hu-
man PDZK1 promoter, EMSAs were performed (Fig. 3A and
B). The EMSAs revealed that PPARa could bind to this ele-
ment in the presence of RXRa (Fig. 3A, closed arrowhead
on lanes 3 and 4). This complex formation was competed by
increasing amounts of the unlabeled self-competitor probe
and ACO PPRE fragments, which is one of the PPARa bind-
ing elements [15], but not by the mutated PPRE probe
(Fig. 3A, lanes 5–10). No protein–DNA complex was observed
when using the mutated PPRE as a radiolabeled probe (lane
11). To conﬁrm that this complex contains the PPARa, we per-
formed supershift experiments (Fig. 3B). Monoclonal antibod-
ies against PPARa and RXRa produced supershifted bands
(Fig. 3B, open arrowheads on lanes 4 and 6, respectively).
As expected, a control antibody had no signiﬁcant eﬀect (lane
8). These data showed that PPARa/RXRa heterodimers bind
to this PPRE sequence in vitro.
To conﬁrm that the PPARa/RXRa heterodimers bind to
this PPRE in cells, we performed ChIP assays. HepG2-tet-
oﬀ-hPPARa cells, cultured in the absence of Dox for 5 days
to express human PPARa, were treated with 100 lM fenoﬁbric
acid for 8 h. These cells were subsequently used for ChIP as-
says. The co-precipitated DNA fragments were detected by
PCR ampliﬁcation. Speciﬁc ampliﬁcation of the PPRE in the
endogenous human PDZK1 promoter was detected when anti-
body for PPARa or RXRa was used, but not in the case of the
pre-immune rabbit IgG (Fig. 3C, upper panel). In contrast, a
second set of primers pair for amplifying another genomic re-
gion about 6-kb upstream of the human gapdh gene that was
expected to interact with neither PPARa nor RXRa showed
a PCR product only using input DNA (Fig. 3C, lower panel).
Taken together, these results indicated that PPARa and
RXRa bind to this PPRE in the human PDZK1 promoter.Fig. 3. PPARa binds to the PPRE of the human pdzk1 gene. (A, B)
EMSAs were performed with 32P-labeled PDZK1 PPRE (PDZK1) or
mutated PDZK1 PPRE (PDZK1 mut) oligonucleotides in the presence
of puriﬁed PPARa and/or RXRa proteins. Unlabeled oligonucleotides
were used at 100- or 300-fold molar excess to the labeled probe to
perform competition assays. Supershift experiments were carried out
using anti-PPARa, anti-RXRa or anti-GAPDH (Control) antibodies.
Closed and open arrowheads indicate the speciﬁc bands and the
supershift bands, respectively. (C) HepG2-tet-oﬀ-hPPARa cells were
treated with fenoﬁbric acid and processed for ChIP assays. Soluble
chromatin was immunoprecipitated with pre-immune rabbit IgG, anti-
PPAPa antibody or anti-RXRa antibody. Immunoprecipitates were
subjected to PCR with a primer-pair speciﬁc to the PDZK1 promoter
(upper). As a negative control, a second set of primers was used to
amplify another genomic region that was expected to interact with
neither PPARa nor RXRa (lower).3.4. Endogenous PPARa induces PDZK1 expression
Finally, to examine whether endogenous PPARa regulates
the human PDZK1 expression, we used human hepatoma cell
line Huh-7 that expressed both PPARa and RXRa proteins
(data not shown). The expression levels of PDZK1, as well
as adipose diﬀerentiation-related protein (ADRP) which is a
known PPAR target gene [10], were increased upon treatment
with GW7647, which has a higher aﬃnity for PPARa than fen-
oﬁbric acid (Fig. 4A and B). These data suggest that endoge-
nous PPARa induces the expression of the human PDZK1.
Activation of PPARa induces the expression of apolipopro-
tein A-I, resulting in elevated HDL cholesterol levels in humans
Fig. 4. PDZK1 expression is regulated by the PPARa agonist in Huh-7 cells. (A) Huh-7 cells were treated with 1 lM GW7647 or DMSO for 24 h.
PDZK1 and ADRP mRNA levels were measured by RT-PCR and normalized to b-actin mRNA, relative to the control set as 1. (B) Huh-7 cells were
treated with 1 lM GW7647 or DMSO for 3 days. Cell lysates were subjected to SDS–PAGE. Immunoblots were performed with anti-PDZK1 or
anti-GAPDH antibodies. The graph represents relative quantities of PDZK1 proteins in Western blot analyses. PDZK1 protein levels were
normalized to GAPDH protein levels, relative to the control set as 1. Values are expressed as the mean ± S.E.M. (n = 3). Signiﬁcant diﬀerences of the
values compared to the control were determined using Students t-test (*P < 0.05, **P < 0.01, ***P < 0.001).
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and LIMP II Analogous-1 (CLA-1), the human homologue of
SR-BI [16]. Here, we demonstrated that ligand-activated
PPARa induced PDZK1 expression. PDZK1 binds to the C ter-
minus of SR-BI and maintains steady state levels of SR-BI in
the liver [2–4]. Recently, Komori et al. [17] established a mouse
model to study human reverse cholesterol transport by coex-
pressing human cla-1, pdzk1 and apolipoprotein A-I genes, and
demonstrated that enhancing CLA-1 expression by human
PDZK1 in the liver modulated HDL cholesterol metabolism
in vivo. Judging from these results, PPARa activators might en-
hance the reverse cholesterol transport in human.
In conclusion, this is the ﬁrst study to characterize the 5 0-
ﬂanking region of the human pdzk1 gene. We show that up-reg-
ulation of PDZK1 expression by PPARa is mediated by the
PPRE. Namely, human PDZK1 is a novel PPARa target gene.
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